Streetbeat News

ESPR

Esperion Therapeutics, Inc.

https://www.esperion.com

Industry

Drug Manufacturers - Specialty & Generic

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

Open

2.03

Mkt cap

414M

Volume

12M

High

2.14

P/E Ratio

-2.48

52-wk high

3.40

Low

1.87

Div yield

N/A

52-wk low

0.87

Esperion Therapeutics, Inc. and Daiichi Sankyo Europe have amended their collaboration agreement with a $125 million deal, which also includes the resolution of pending litigation between the two companies. This amendment is expected to strengthen the partnership and enhance the commercial prospects for Esperion's products in Europe.

Portfolio Pulse from Benzinga Newsdesk

January 03, 2024 | 12:07 pm

Global Mofy Metaverse Limited (GMM) shares plummeted by 37.2% after announcing a $10 million follow-on offering. Other stocks also experienced declines, including Canaan Inc., Bitdeer Technologies Group, TeraWulf Inc., Applied Optoelectronics, Inc., and several others. Notably, Hut 8 Corp. received court approval to proceed with mining operations amid Celsius Network's bankruptcy, and Coinbase Global's director sold over 100k shares. Lyft shares dropped after a Nomura downgrade and insider selling by the CAO.

Portfolio Pulse from Avi Kapoor

December 29, 2023 | 3:45 pm

DouYu International Holdings Limited (NASDAQ:DOYU) announced a share repurchase program of up to $20 million of ordinary shares in the form of ADSS, causing its shares to rise by 14.2% to $0.8320. Other stocks experienced significant movements in Thursday's mid-day session, with various companies seeing substantial gains and losses for diverse reasons, including FDA guidance, analyst ratings, public offerings, and patent lawsuit outcomes.

Portfolio Pulse from Avi Kapoor

December 28, 2023 | 6:07 pm

Four health care stocks are showing signs of being overbought according to their Relative Strength Index (RSI) values, which may indicate a potential short-term pullback. Esperion Therapeutics (ESPR), Celldex Therapeutics (CLDX), Verrica Pharmaceuticals (VRCA), and MacroGenics (MGNX) have all seen significant price increases recently, with their RSI values exceeding the typical overbought threshold of 70. This suggests that these stocks may experience a downturn in the near future as traders who rely on momentum indicators might consider taking profits.

Portfolio Pulse from Avi Kapoor

December 20, 2023 | 1:31 pm

Esperion Therapeutics announced that the FDA updated the LDL-C lowering indication for its drugs NEXLETOL and NEXLIZET, causing ESPR shares to surge by 46%. Ensysce Biosciences released a study showing efficacy data for its drug PF614, leading to a 62% jump in ENSC shares. Moderna's stock rose by 12% after announcing positive follow-up data from a Phase 2b study of mRNA-4157-P201 in partnership with Merck for treating high-risk melanoma.

Portfolio Pulse from ryanfaloona@benzinga.com

December 14, 2023 | 1:47 pm

Nxu, Inc. (NASDAQ:NXU) shares surged by 42.1% in pre-market trading after announcing a letter of intent for investment in Lynx Motors. Other stocks showed significant movement in pre-market trading, with XBP Europe Holdings, Inc. (NASDAQ:XBP) and Hanryu Holdings, Inc. (NASDAQ:HRYU) among the top gainers. Conversely, Amtech Systems, Inc. (NASDAQ:ASYS) and Regis Corporation (NYSE:RGS) were among the biggest losers, with RGS facing delisting proceedings from the NYSE. Adobe Inc. (NASDAQ:ADBE) also fell after issuing a weak sales forecast for full-year 2024 despite positive fourth-quarter earnings.

Portfolio Pulse from Avi Kapoor

December 14, 2023 | 1:27 pm

In Thursday's pre-market session, several healthcare stocks experienced significant movements. Reshape Lifesciences (RSLS) led the gainers with a 22.3% increase, while NextCure (NXTC) saw the largest drop among the losers, falling 19.3%. Other notable gainers included Esperion Therapeutics (ESPR), Femasys (FEMY), Bio-Path Holdings (BPTH), Codexis (CDXS), and Akso Health Group (AHG). On the losing side, Apellis Pharmaceuticals (APLS), Ocular Therapeutix (OCUL), Pasithea Therapeutics (KTTA), Monte Rosa Therapeutics (GLUE), and Assure Holdings (IONM) also saw their stock prices decline.

Portfolio Pulse from Benzinga Insights

December 14, 2023 | 1:07 pm

Esperion announced that the FDA has updated the LDL-C lowering indication for its drugs NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets. This immediate change reflects the FDA's initiative to modernize drug labels and Esperion's efforts to broaden the indications for its products.

Portfolio Pulse from Benzinga Newsdesk

December 13, 2023 | 9:04 pm

JP Morgan analyst Jessica Fye has reinstated coverage on Esperion Therapeutics (NASDAQ:ESPR) with a Neutral rating.

Portfolio Pulse from Benzinga Newsdesk

November 20, 2023 | 1:26 pm

Esperion Therapeutics (NASDAQ:ESPR) has received 4 bullish analyst ratings in the last quarter with an average price target of $15.25, indicating a significant upside from the current price of $0.9199. The average price target has risen by 69.44% over the past month, suggesting a positive outlook from analysts on the stock.

Portfolio Pulse from Benzinga Insights

November 13, 2023 | 6:00 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.